Niclosamide

Generic Name: Niclosamide

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₈Cl_₂N_₂O_₄

CAS Number: 50-65-7

Unique Ingredient Identifier: 8KK8CQ2K8G

Background: Niclosamide is an antihelminthic used for the treatment of tapeworm infections. Helminths (worms) are multicellular organisms that infect very large numbers of humans and cause a broad range of diseases. Over 1 billion people are infected with intestinal nematodes, and many millions are infected with filarial nematodes, flukes, and tapeworms. They are an even greater problem in domestic animals.

Niclosamide, once marketed in the US under the brand name Niclocide, was voluntarily withdrawn from market by Bayer in 1996.

Indication: For the treatment of tapeworm and intestinal fluke infections: Taenia saginata (Beef Tapeworm), Taenia solium (Pork Tapeworm), Diphyllobothrium latum (Fish Tapeworm), Fasciolopsis buski (large intestinal fluke). Niclosamide is also used as a molluscicide in the control of schistosomiasis.

Associated Conditions: Helminthic infection, Tapeworm infestation

Clinical Trials

UCSD and Hyundai Bio to Evaluate Xafty for Long COVID Treatment

8 months ago

• UC San Diego and Hyundai Bioscience will collaborate on an investigator-initiated trial to assess Xafty, a niclosamide-based antiviral, for treating Long COVID. • Xafty has shown promise in Phase 2 trials by improving symptoms faster than existing treatments, especially in high-risk COVID-19 patients. • Preclinical studies suggest Xafty may alleviate Long COVID symptoms through anti-inflammatory and neuroprotective mechanisms, including dopamine production. • The trial aims to confirm niclosamide's potential to address the complex symptoms of Long COVID, offering a new treatment option for affected individuals.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy